06.01.26 -- CGT Manufacturing Shifts From Capacity To Strategy

Discover how standardized, scalable platforms modernize viral vector production, helping developers accelerate clinical timelines and deliver advanced therapies to patients efficiently.

Explore how incorporating a 0.2% animal-free soy peptone supplement into chemically defined media increased CHO IgG production by 30% to 60%.

Through speed, transparency, and close collaboration, this pharmaceutical company was able to switch vendors seamlessly, maintaining virtually uninterrupted manufacturing operations.

Every drop of high-value biologic lost in fill finish is money left on the table. Protect your yield with these stage-by-stage methods in your operation across filtration, filling, and sterility testing.

Integrated real-time visibility transforms outsourced manufacturing from fragmented, reactive coordination into proactive execution, stronger alignment, improved accountability, and timeline confidence.

Read how treating cryopreservation as a validated, controlled input minimizes downstream variability, directly improving product consistency and clinical outcomes for patients.

Learn how lentiviral vector processes evolve for in vivo and ex vivo CAR‑T—covering yield, purity, scalability, and shifting regulatory demands for safe, consistent systemic delivery.